-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fecal microbiota transplantation (FMT) is very effective against repeated infections of Clostridium difficile , but it has inherent risks.
Fecal microbiota transplantation (FMT) is very effective against repeated infections of Clostridium difficile , but it has inherent risks.
This is an open-label, single-group feasibility phase 1 study conducted in Canada, recruiting patients with mild to moderate C.
From September 19, 2018 to February 28, 2020, a total of 19 adult patients (median age 65 years; 12 females, 7 males) who had at least two C.
Within 40 days of initial treatment, 15 of the 19 patients (79%) did not recur with C.
After MET-2 treatment, the patient's life treatment was significantly improved, and the alpha diversity in the fecal microbial composition was also significantly improved.
In conclusion, MET-2 has shown good safety, tolerability and effectiveness for patients with recurrent Clostridium difficile infection.
Original source:
Dina Kao, et al.
The effect of a microbial ecosystem therapeutic ( MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial in this message